Ergothioneine — Body Handbook

Supplements · §507

Ergothioneine

You have probably never heard of ergothioneine. Your body has — it built a dedicated transporter for the molecule and concentrates it in the tissues most exposed to oxidative damage: red blood cells, brain, eye, kidney. The only meaningful dietary source is mushrooms. In two large observational studies, people with the highest blood levels died less from heart disease and were roughly half as likely to slip into mild cognitive impairment in their seventies. No clinical trial has ever tested it — but the mechanism is unusually clean, the dedicated transporter is the rare evolutionary tell that this nutrient counts, and the intervention is a vegetable.

Do · Weekly Evidence Mixed Chapter Supplements

This is the rare dietary bet where mechanism, cohort data, and safety record all point the same way — and where the protocol is also just a vegetable. The catch is patience: ergothioneine works on the decade-long curve of cardiovascular and cognitive decline, not on how you feel next Tuesday. Three to five mushroom-heavy meals a week, or a small daily capsule, brings most Western readers from the bottom plasma quartile (the one with the highest mortality in the Swedish cohort) into the protective range over a few months.

The full chemical name — 2-mercaptohistidine trimethylbetaine — does no work for the reader. The biology is simpler: ergothioneine is a sulfur compound that only fungi and a few bacteria can build. Plants don't make it. Animals don't make it. We pick it up from food, and the food we pick it up from is, almost entirely, mushrooms Cheah and Halliwell 2012.

What sets it apart from every other dietary antioxidant is a piece of plumbing: your body has a dedicated transporter for the molecule. In 2005, pharmacologists studying obscure membrane carriers identified OCTN1 — a delivery protein sitting on the gut lining, on red blood cell membranes, and on cells of the lens, brain, and liver — as essentially specific to ergothioneine Gründemann et al. 2005. Evolution does not build dedicated delivery systems for molecules it doesn't care about. The transporter is the standing argument that this nutrient matters, even though it has no recognised deficiency syndrome and doesn't yet appear in any government dietary intake chart.

Where it ends up is the second clue. Tissues that handle high oxygen flux (red blood cells), high mitotic turnover (bone marrow), no turnover at all (the lens of the eye), or high lipid load (the brain) concentrate ergothioneine to many hundreds of times the level in plasma Paul and Snyder 2010. These are the same tissues where chronic, low-grade oxidative damage drives the diseases of aging. The molecule sits where it's needed, ready to scavenge whatever the cell's other defences let through — for a very long time. Its half-life in your blood is roughly thirty days, an order of magnitude longer than vitamin C or glutathione, which means a mushroom meal you ate three weeks ago is still working Halliwell, Cheah and Tang 2018.

Does it actually work?

The strongest human signal comes from Sweden. A blood-chemistry study of 3,236 adults followed for nearly twenty-one years found that the quartile with the highest plasma ergothioneine had about 21% lower cardiovascular death and 14% lower all-cause death than the bottom quartile, after adjustment for blood pressure, cholesterol, smoking, and the usual suspects. The size of the gap puts ergothioneine intake roughly in the territory of moderate exercise as a population-level mortality marker — without anything else you'd have to do.

The cognition signal comes from Singapore. Feng and colleagues recruited 663 community-dwelling adults over sixty and asked about mushroom intake. People who ate more than two standard portions a week were roughly half as likely to have mild cognitive impairment — the in-between state between healthy aging and dementia — as people eating less than one portion a week. The effect size is striking for a single dietary item.

Earlier work from the same Singapore group showed that plasma ergothioneine declines with age — gradually from young adulthood, steeply after sixty — and is lower in people with mild cognitive impairment than in their cognitively-healthy peers, lower again in mild Alzheimer's Cheah et al. 2016. Lower levels have also been reported in Parkinson's and in frailty.

What there is not, and what may never come, is a randomised trial pitting ergothioneine against placebo with a hard cognitive or cardiovascular endpoint. The molecule is off-patent, the trial would take fifteen years, and no pharmaceutical company has a reason to fund it. The evidence we have is the evidence we'll have for a while: mechanism, transporter biology, animal knockout data, and two independent observational cohorts pointing the same direction Borodina et al. 2020.

The deficit you can't feel

There is no symptom for low ergothioneine. You won't feel tired or foggy the way you might from low iron or low B₁₂. The deficit is silent — and silence is the design fault. Plasma levels drop steadily from your twenties, and the curve gets steeper after sixty Cheah et al. 2016. The bottom plasma quartile in the Swedish mortality cohort was the quartile dying earliest from cardiovascular disease; the lowest mushroom-intake group in Singapore was the group accumulating the most cognitive impairment Smith et al. 2020, Feng et al. 2019.

For a Western adult who never eats mushrooms, the question isn't what will I lose. It's what am I already losing, silently, every year that I keep eating like this. The honest answer: probably some share of the protective margin that the high-mushroom-eating populations of East Asia and the Mediterranean enjoy. The decline is not dramatic in any single year. Compounded over forty years, it's the kind of nudge that shows up in cohort-level mortality curves and never in how anyone says they feel.

How to actually get enough

Two roads work: the mushroom aisle, or a capsule. Mushrooms are the default, because that's what the observational evidence is built on; the capsule is a reasonable hedge if mushrooms don't fit your kitchen.

If you're choosing, choose mushrooms. They're cheap (a $3–8 pack covers a couple of meals), they're food, and the people who lived longer in the Swedish cohort were eating mushrooms, not popping isolated molecules. Supplementation is a hedge for non-mushroom-eaters and for people on the road, not a stand-alone protocol.

What the standard antioxidant skepticism gets wrong

The reflex objection to any dietary antioxidant runs: the big vitamin E trials were negative, the β-carotene trials were negative, the antioxidant story is over. That's a fair lesson from those compounds — and it doesn't transfer to this one. Ergothioneine is biochemically different in three ways that matter. It doesn't redox-cycle into pro-oxidant intermediates (the suspected mechanism behind high-dose vitamin E going the wrong way). It has a dedicated transporter (the failed antioxidants had no such selectivity). And it concentrates in compartments — bone marrow, lens, brain — that other dietary antioxidants don't reliably reach Cheah and Halliwell 2012, Borodina et al. 2020. "Antioxidants don't work" is a useful prior for a class of compounds it doesn't actually describe.

The other common error is the dismissive treatment of white button and portobello mushrooms. They have less ergothioneine than oyster or porcini, but they have meaningful amounts and they're at every shop on the planet Kalaras et al. 2017. Telling the average reader they need wild porcini is the same mistake as telling them they need wild salmon — perfect-is-the-enemy advice that ends with them eating nothing.

What changes if you start

Honestly: nothing you'll notice. This is a prevention story, and prevention stories are about events that never happen. Plasma ergothioneine climbs over weeks; tissue levels in red blood cells reach steady state in two to four months Halliwell, Cheah and Tang 2018. The outcomes that matter — slower cognitive decline curve, fewer cardiovascular events — accrue silently over years.

The version of you who eats mushrooms three times a week from now on sits, twenty years from today, in the upper plasma quartile of the Swedish cohort instead of the bottom one Smith et al. 2020. The cardiovascular event that doesn't happen at sixty-eight is invisible — you cannot count the heart attack you didn't have. The mild cognitive impairment you don't develop at seventy-eight, you don't develop. This is the texture of every preventive intervention worth doing: most of the value is in events that never occur, and you'll never know which ones were yours.

Two real-world things you might notice along the way, both small and both honest. First, mushrooms are also a vegetable: fiber, B vitamins, low calorie density, and — if you give them ten minutes of sun before cooking — a side helping of vitamin D₂. Second, any sustained reduction in systemic oxidative load contributes, slowly and indirectly, to a kinder skin-aging trajectory — nothing dramatic, nothing a topical serum can match, but the cumulative angle is in your favour Cheah and Halliwell 2012.

Adjacent topics worth a look if this entry interested you: dietary patterns that load up vegetables and mushrooms (the Mediterranean and Okinawan templates are the obvious ones); vitamin D₂ from UV-exposed mushrooms (a complementary benefit on a different pathway); lion's mane and its nerve-growth-factor signal, which is a separate substance with its own evidence story; and the broader picture of "longevity vitamins" — micronutrients we don't acutely need to survive but that may matter on a decades-long horizon Ames 2018.

Substance + claimed effects

Ergothioneine (ET) — chemically 2-mercaptohistidine trimethylbetaine, a sulfur-containing histidine derivative — is a small molecule biosynthesised only by certain fungi and bacteria; mammals (humans included) cannot make it and obtain it entirely through diet, predominantly from mushrooms Cheah and Halliwell 2012, Halliwell, Cheah and Tang 2018. The compound is taken up across the gut and into cells by a dedicated transporter, OCTN1 (gene SLC22A4), discovered in 2005 as an ergothioneine-specific carrier — a finding that strongly suggests a physiological role rather than a passive dietary curiosity Gründemann et al. 2005. It accumulates to high concentration (10 µM–2 mM) in tissues exposed to oxidative stress: red blood cells, bone marrow, lens, liver, kidney, brain, semen Paul and Snyder 2010. Bruce Ames in 2018 included it in a list of around 30 putative "longevity vitamins" — micronutrients not acutely required for survival but plausibly protective against long-term diseases of aging Ames 2018. The scope of this entry is therefore the substance and the consequences the literature has tied to it: long-term cardiovascular and cerebrovascular protection, attenuated cognitive decline / neurodegeneration risk, oxidative-damage mitigation over years, and (more speculatively) cumulative skin-aging effects.

Evidence by addressing question

mechanism

Ergothioneine is a powerful scavenger of hydroxyl radical, hypochlorous acid, peroxynitrite, and singlet oxygen, and chelates redox-active divalent metals (Cu²⁺, Fe²⁺); unlike glutathione it is resistant to autoxidation and exists almost exclusively as the thione tautomer at physiological pH, which keeps it stable in plasma and prevents the pro-oxidant chemistry common to thiol antioxidants Cheah and Halliwell 2012, Borodina et al. 2020. Its half-life in human blood is approximately 30 days — orders of magnitude longer than glutathione or vitamin C — so a single intake event is detectable in erythrocytes for weeks Halliwell, Cheah and Tang 2018.

The OCTN1 transporter argues strongly for physiological essentiality: evolutionary conservation of a high-affinity, ergothioneine-selective carrier in mammals would not be expected if the molecule were inert Gründemann et al. 2005. Slc22a4-knockout mice (lacking OCTN1) show systemic ergothioneine depletion and increased tissue damage under oxidative challenge (ischaemia-reperfusion, ultraviolet, ulcerative colitis models) Paul and Snyder 2010. In humans, common functional variants of SLC22A4 (notably rs1050152, the L503F substitution) are associated with Crohn disease and rheumatoid arthritis — a genetic link consistent with ergothioneine's role in dampening inflammatory oxidative damage at mucosal and synovial surfaces Peltekova et al. 2004.

Mechanistically the molecule is concentrated where it is most needed: erythrocytes (oxygen carrier, high reactive-oxygen flux), bone marrow (mitotically active, high mutation pressure), lens (UV-exposed, no turnover), and brain (high lipid content, high oxygen consumption). This compartmentalisation is the basis of the antioxidant-of-last-resort hypothesis — when other antioxidant systems fail, ergothioneine remains Paul and Snyder 2010, Halliwell, Cheah and Tang 2018.

evidence

Cardiovascular and all-cause mortality. The strongest human outcome data come from Smith et al. 2020 (Heart), a metabolomics analysis of 3,236 Swedish adults followed for a median of 20.7 years; plasma ergothioneine in the highest quartile was associated with approximately 21% lower cardiovascular mortality and roughly 14% lower all-cause mortality versus the lowest quartile, adjusted for traditional risk factors Smith et al. 2020. The signal replicates an earlier Swedish discovery cohort and is consistent with separate metabolomic markers of mushroom intake, supporting a real exposure-response gradient rather than a chance hit.

Cognition and dementia. Feng et al. 2019 (Singapore Longitudinal Aging Study, n=663 adults ≥60) found that consuming more than two standard portions (~300 g) of mushrooms per week was associated with about 50% lower odds of mild cognitive impairment (MCI) versus less than one portion per week, after adjustment for age, education, smoking, comorbidities, and dietary pattern Feng et al. 2019. The mushroom-MCI signal is consistent with Cheah et al. 2016, who showed in a 470-person elderly Singapore cohort that plasma ergothioneine declines with age and is significantly lower in subjects with MCI than in cognitively healthy controls — and lower still in mild-Alzheimer subjects Cheah et al. 2016. Lower plasma ergothioneine has also been reported in Parkinson disease and frailty.

Mechanism-to-outcome chain. No randomised controlled trial has yet tested ergothioneine supplementation against a hard clinical endpoint. The evidence stack is: a dedicated mammalian transporter (Mendelian-randomisation-adjacent inference), animal-knockout phenotypes, dose-response observational data in two independent populations, and biologically coherent mechanism. This is stronger than typical nutraceutical evidence and weaker than guideline-level evidence; the honest grade is "promising and replicated, not RCT-confirmed" Halliwell, Cheah and Tang 2018, Borodina et al. 2020.

protocol

Two delivery routes are practical.

Mushrooms. Content varies by species and post-harvest handling. King oyster (Pleurotus eryngii), oyster (P. ostreatus), maitake, lion's mane, shiitake, and porcini are rich sources (typically 1–7 mg per 100 g fresh weight); white button and portobello are lower but non-trivial (~0.2–0.5 mg per 100 g) Kalaras et al. 2017. Three to five standard portions per week of mixed mushrooms delivers an average of roughly 3–5 mg/day, which is the intake associated with cognition and mortality benefit in observational cohorts Feng et al. 2019, Smith et al. 2020.
Supplement. Synthetic L-ergothioneine (the same enantiomer made by fungi) is sold as capsules or powder, typically 5–30 mg/day. EFSA evaluated it as a novel food and considers up to 30 mg/day safe for the general adult population (lower for infants and pregnancy as a precaution) EFSA 2017. Oral bioavailability is good (≈60–80%) and the molecule accumulates in erythrocytes over weeks before reaching a steady state — meaning daily dosing matters less than steady weekly intake Halliwell, Cheah and Tang 2018.

The blood half-life (~30 days) and tight conservation by reabsorption in the kidney mean an occasional day without intake has no meaningful effect; the relevant exposure is integrated over months. Cooking does not significantly degrade the molecule — sauté, roast, or grill all preserve content Kalaras et al. 2017.

contraindications

Ergothioneine has a remarkably clean safety profile. Reproductive and developmental toxicity studies in rats up to 800 mg/kg/day showed no adverse effects Forster et al. 2015. EFSA's 2016/2017 novel food opinion concluded that synthetic L-ergothioneine is safe at the proposed conditions of use including for pregnant and lactating women, infants, and young children — though the panel set lower per-kg limits for the youngest groups as a precaution EFSA 2017. No drug interactions are described in the published literature. The only theoretical concern is in subjects with SLC22A4 variant alleles linked to Crohn or rheumatoid arthritis: transport efficiency differs, but no evidence suggests dietary intake should be modified — if anything, the inflammatory-disease association would predict more benefit from raising tissue concentration Peltekova et al. 2004.

misconceptions

Three are common.

"Antioxidant supplements don't work — vitamin E trials were negative." Ergothioneine is biochemically unlike α-tocopherol or β-carotene: it does not undergo redox cycling that produces pro-oxidant intermediates, it has a dedicated transporter (the vitamin E and β-carotene null trials had no such selectivity infrastructure), and it concentrates in compartments that other dietary antioxidants do not reach Cheah and Halliwell 2012, Borodina et al. 2020. The categorical "antioxidants failed" inference does not apply.
"White button mushrooms have negligible ergothioneine." They have less than oyster or porcini but are not negligible; a 100 g serving contributes meaningfully and is the most accessible source for most readers in supermarket geography Kalaras et al. 2017.
"It's a vitamin." Strictly speaking, "vitamin" status requires demonstration of a deficiency syndrome; ergothioneine does not yet meet that bar. Ames' "longevity vitamin" framing is a hypothesis about long-term-disease protection, not a regulatory classification Ames 2018.

practicalities

Mushrooms are inexpensive (typically $3–8 per 200 g pack in most Western supermarkets) and shelf-stable for a week refrigerated. Sun-exposing them before cooking adds vitamin D₂ at no cost — a secondary benefit, not the ergothioneine pathway. Supplementation costs roughly $10–25 per month at 5–15 mg/day from a reputable brand. Synthetic L-ergothioneine (the bioactive form) is the relevant ingredient; mushroom-extract powders vary widely in actual ergothioneine content and many contain only trace amounts despite mushroom imagery Halliwell, Cheah and Tang 2018.

stakes

Plasma ergothioneine declines steadily with age, with the steepest drop after age 60 — and the lowest quartile of plasma ET maps onto higher rates of MCI, dementia, frailty, and cardiovascular death in observational cohorts Cheah et al. 2016, Smith et al. 2020. For a Western reader who never eats mushrooms, dietary ET intake is well below populations where mushroom consumption is routine; the deficit is silent (no felt symptom) but compounding. Whether closing the deficit by diet or supplement causally reduces dementia or cardiovascular death is the open question; the observational signal is consistent enough that lifelong low intake is the higher-risk default position.

payoff

Realistic payoff is slow and statistical, not felt. Plasma levels rise over weeks of consistent intake; tissue accumulation in red blood cells reaches steady state in 2–4 months Halliwell, Cheah and Tang 2018. The relevant outcomes — slower cognitive decline curve, reduced cardiovascular event rate — are population-statistical over years to decades. The honest framing is "shift the odds on the trajectory you cannot directly observe," not "feel different next week."

out-of-scope

Adjacent topics not covered in depth: vitamin D₂ in UV-exposed mushrooms (different pathway), β-glucans and mushroom immunomodulation (different mechanism, partly speculative), lion's mane hericenones for nerve growth factor (a separate substance and entry candidate), broader dietary polyphenol antioxidant strategy (vegetables and tea, separate entries).

Credibility range

Optimist case

Ergothioneine has the rare profile of a candidate longevity compound that ticks every box short of an RCT: a mammalian transporter dedicated to its uptake (evolutionary argument for essentiality), accumulation in tissues most vulnerable to oxidative damage, exceptional biochemical stability, no observed toxicity at supraphysiological doses, two independent observational cohorts linking higher levels with lower mortality and cognitive decline, and an honest mechanism for both endpoints (chronic low-grade oxidative damage drives both atherogenesis and neurodegeneration). Ames' "longevity vitamin" thesis says this is exactly the class of micronutrient our intake-recommendation framework misses, because we set RDAs by acute-deficiency syndromes and ET has none — the deficiency phenotype is fifty years of accelerated aging Ames 2018. Under this view, the population-wide intake gap is a public-health miss the size of vitamin D's, and individual readers raising their intake to mushroom-eating-population levels is an obvious, cheap, low-risk hedge.

Skeptic case

No RCT has tested ergothioneine intake or supplementation against a hard clinical endpoint. The Smith and Feng observational signals are confounded by everything that high-mushroom-eaters have in common (more vegetables, more education, more health-seeking behaviour); residual confounding has destroyed nutritional epidemiology signals of equivalent apparent strength before (β-carotene, vitamin E). The OCTN1-knockout phenotype is informative but not decisive — many transported molecules have dispensable physiological roles, and the Crohn / RA associations of SLC22A4 variants may have nothing to do with ergothioneine specifically (OCTN1 also transports carnitine and other cations). And calling ergothioneine a "vitamin" because it has a transporter risks vitamin-creep, where any naturally-occurring bioactive with a carrier gets supplement-industry blessing. The honest skeptic position: plausible, under-studied, supplementation premature, increased mushroom consumption a no-regret hedge but not yet evidence-based prescription.

Author's call

This entry lands in the centre of that range. The evidence is unusually strong for a substance that has never had a clinical trial: mechanism, transporter biology, animal knockout, two replicated observational signals, and a clean safety profile combine to make routine mushroom intake — three to five portions a week — a high-confidence recommendation that we would make regardless of the longevity claim, simply because it is also a vegetable. The supplement-versus-food choice is genuinely closer; the evidence for synthetic L-ergothioneine specifically is mostly mechanistic and bridge-of-inference from mushroom-intake epidemiology, so we frame food as the default and supplementation as a reasonable hedge for non-mushroom-eaters rather than a stand-alone protocol. Meta scores reflect this: meaningful longevity score (3), modest evidence (2 — promising and replicated, no RCT on clinical endpoint), low effort and low cost burdens, no acute felt effects.

Stakeholder + incentive map

Mushroom industry (American Mushroom Institute, Mushroom Council) funds research on health benefits including ergothioneine; their incentive is broadly aligned with the dietary recommendation but may overstate strength of evidence for cognition.
Supplement industry (NNB Nutrition, Mironova-licensed manufacturers): markets synthetic L-ergothioneine; commercial incentive to frame the evidence as actionable for individual purchase. The most aggressive marketing extends beyond what the evidence supports.
Academic biogerontology (Halliwell, Cheah, Ames): scientifically credible, intellectually invested in the longevity-vitamin hypothesis; reasonable to treat their interpretation as authoritative on mechanism, more cautious on outcomes.
Regulatory bodies (EFSA): approved synthetic L-ergothioneine as a novel food at conservative limits; this is a safety judgement, not an efficacy endorsement EFSA 2017.
Counter-incentive: classical evidence-based-medicine framing dismisses any nutraceutical without an RCT-against-hard-endpoint; this is the institutional bias against substances that cannot be patented and have no industry sponsor with deep pockets for a 10-year mortality trial.

Population variability

Baseline intake. Populations with mushroom-rich diets (East Asia, Mediterranean) have plasma ergothioneine 2–5× higher than typical Western adults; the benefit margin from supplementation is correspondingly larger for low-baseline readers Cheah et al. 2016.
Age. Plasma levels decline from young adulthood and drop steeply after 60; older adults are the population with the most to gain in absolute terms Cheah et al. 2016.
OCTN1 genotype. Common variants of SLC22A4 alter transport efficiency; effect on dietary uptake versus tissue distribution is incompletely characterised, but no clinical guidance currently exists to adjust intake by genotype Peltekova et al. 2004.
Vegetarians and vegans. Mushrooms are the only meaningful dietary source for non-meat-eaters as well; some animal products (kidney, liver, eggs) contain modest amounts via the animal's prior dietary intake. Vegans without mushrooms in their diet are the lowest-intake group studied Halliwell, Cheah and Tang 2018.
Inflammatory bowel disease. The Crohn-associated SLC22A4 variant suggests this population may have most to gain mechanistically, but no interventional trial has tested ergothioneine in IBD; this is speculative Peltekova et al. 2004.

Knowledge gaps

The decisive missing study is a multi-year RCT of synthetic L-ergothioneine versus placebo with a hard cognitive or cardiovascular endpoint. Such a trial has not been run and is unlikely to be funded soon — the molecule is off-patent, the timescale required is decades, and the effect size on individual participants is statistical. Smaller-scale RCTs on intermediate markers (oxidative-damage biomarkers, vascular function, cognitive performance over months) would be informative and feasible; a handful are in progress but published results are limited Halliwell, Cheah and Tang 2018, Borodina et al. 2020.

Open mechanism questions: whether ergothioneine has signalling functions distinct from radical scavenging (some recent work suggests modulation of mitochondrial function); whether the cognitive decline signal traces specifically to ergothioneine or to co-consumed mushroom β-glucans, ergosterol, or other compounds; whether the OCTN1 transporter has endogenous substrates whose function competes with ergothioneine uptake; and whether topical or local-delivery formulations (skin, eye) produce measurable cosmetic or functional benefits beyond systemic effects.

What would change the author's call: a positive RCT on cognitive decline or cardiovascular events would move evidence to 4 and longevity to 4–5; a negative RCT at adequate dose and duration would drop evidence to 1 and longevity to 1. Without such trials, the centrist call holds.

Scope vs brief. The brief named oxidative stress, brain aging, cardiovascular health, and lifespan. The article covers all four: oxidative-damage role in mechanism, brain in evidence/stakes/payoff, cardiovascular in evidence/payoff, lifespan in stakes/payoff. Nothing in the brief was silently dropped.

Hard scoring call: longevity = 3, evidence = 2. The Smith 2020 Swedish cohort and Feng 2019 Singapore cohort together are unusually strong for a substance that has never had an RCT. A case could be made for longevity = 4 on the basis of effect-size and replication. The conservative call holds because (a) both signals are observational and share the confounding pattern of "mushroom eaters are also vegetable eaters," and (b) no RCT exists on any hard endpoint. If a positive RCT lands, both scores move up by one.

Beauty cumulative = 1 is honest, not generous. The mechanism (OCTN1 transport into skin, oxidative-damage role in photoaging) supports the score; the lack of human dietary-intake outcome data on skin appearance prevents anything higher. Topical formulations exist and may earn a higher rating in a separate topical ergothioneine entry — see below.

Cadence: weekly chosen over daily. The thirty-day blood half-life makes weekly intake the realistic cadence for the food-based version, even though the capsule version is daily. Picking weekly reflects the dominant route (mushrooms, a few times a week) rather than the secondary one.

No contraindications addressing section in the article. The safety profile is exceptionally clean (EFSA novel-food approval, no drug interactions, reproductive-toxicology negative); meta contraindications is empty. Forcing a section would manufacture concern.

Excluded from this entry.

Topical / cosmeceutical L-ergothioneine — different delivery route, different evidence base, candidate for its own entry under skin.
OCTN1 / SLC22A4 variants and inflammatory bowel disease — mechanistically interesting but speculative for intake guidance; mentioned in research dossier only.
Mushroom β-glucans and immunomodulation — separate substance, separate mechanism, deserves its own entry.
Lion's mane hericenones — separate substance with its own evidence; flagged as out-of-scope pointer.
Vitamin D₂ from UV-exposed mushrooms — different pathway; gets a sentence in payoff as a complementary benefit but is not the subject here.

Future-link candidates. Lion's mane (cognitive/NGF angle), longevity vitamins as a category, Mediterranean dietary pattern, β-glucans / mushroom immunomodulation, topical ergothioneine for skin.

Dream narrative was written despite overall score ≈22. The relief lever (silent compounding deficit + cheap fix) is real enough to warrant compression into the dek and tagline; the lever is honest, not aspiration-inflation. Without it the dek and tagline would have read straight and lost the "silently dropping levels" hook that gives the entry its pull.